Efficient lung cancer-targeted drug delivery a nanoparticle/MSC system.
10.1016/j.apsb.2018.08.006
- Author:
Xusheng WANG
1
;
Haiyan CHEN
2
;
Xiaowei ZENG
1
;
Wenpeng GUO
3
;
Yu JIN
3
;
Shan WANG
4
;
Ruiyun TIAN
4
;
Yanjiang HAN
5
;
Ling GUO
6
;
Jimin HAN
4
;
Yaojiong WU
2
;
Lin MEI
1
Author Information
1. School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou 510275, China.
2. Tsinghua-Berkeley Shenzhen Institute (TBSI), Tsinghua University, Shenzhen 518055, China.
3. The First Affiliated Hospital of Shenzhen University (Shenzhen Second People׳s Hospital), Shenzhen 518000, China.
4. School of Life Sciences, Tsinghua University, Beijing 100084, China.
5. NanFang PET/CT Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
6. Department of Biology and Shenzhen Key Laboratory of Cell Microenvironment, South University of Science and Technology of China, Shenzhen 518055, China.
- Publication Type:Journal Article
- Keywords:
Drug delivery;
KrasG12D;
Lung cancer;
Mesenchymal stem cells;
Nanoparticle
- From:
Acta Pharmaceutica Sinica B
2019;9(1):167-176
- CountryChina
- Language:English
-
Abstract:
Low targeting efficiency limits the applications of nanoparticles in cancer therapy. The fact that mesenchymal stem cells (MSC) trapped in the lung after systemic infusion is a disadvantage for cell therapy purposes. Here, we utilized MSC as lung cancer-targeted drug delivery vehicles by loading nanoparticles (NP) with anti-cancer drug. MSC showed a higher drug intake capacity than fibroblasts. In addition, MSC showed predominant lung trapping in both rabbit and monkey. IR-780 dye, a fluorescent probe used to represent docetaxel (DTX) in NP, delivered MSC accumulated in the lung. Both MSC/A549 cell experiments and MSC/lung cancer experiments validated the intercellular transportation of NP between MSC and cancer cells. assays showed that the MSC/NP/DTX drug delivery system exerted primary tumor inhibition efficiency similar to that of a NP/DTX drug system. Collectively, the MSC/NP drug delivery system is promising for lung-targeted drug delivery for the treatment of lung cancer and other lung-related diseases.
